# A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

> **NCT02016755** · PHASE2 · COMPLETED · sponsor: **AnGes USA, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Critical Limb Ischemia
- Vascular Diseases
- Peripheral Arterial Disease

## Interventions

- **BIOLOGICAL:** HGF Plasmid

## Key facts

- **NCT ID:** NCT02016755
- **Lead sponsor:** AnGes USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-03-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02016755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02016755, "A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02016755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*